Focus: QED Therapeutics is a Palo Alto-based biotech focused on small molecule tyrosine kinase inhibitors targeting rare diseases and oncology indications. The company operates across five therapeutic areas including neurology, rare diseases, oncology, metabolic diseases, and ophthalmology.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Hot — 66 jobs added in 30d
Net +36 (66 new, 30 removed). Aggressive expansion phase.
Strong fit for early-to-mid career professionals seeking pipeline exposure in rare disease/oncology, but career stability depends on successful Phase 3 readouts in next 12-24 months.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for QED Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from QED Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles